106,271 Shares in Penumbra, Inc. $PEN Bought by Norges Bank

Posted by Brenda Bartman on Jun 9th, 2026

Norges Bank purchased a new position in shares of Penumbra, Inc. (NYSE:PEN – Free Report) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 106,271 shares of the company’s stock, valued at approximately $33,041,000.

Several other hedge funds have also recently modified their holdings of PEN. Royal Bank of Canada lifted its holdings in shares of Penumbra by 35.8% during the first quarter. Royal Bank of Canada now owns 19,332 shares of the company’s stock worth $5,169,000 after purchasing an additional 5,092 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Penumbra by 209.1% during the second quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock worth $70,000 after purchasing an additional 184 shares during the period. Cerity Partners LLC lifted its holdings in shares of Penumbra by 22.3% during the second quarter. Cerity Partners LLC now owns 10,030 shares of the company’s stock worth $2,574,000 after purchasing an additional 1,829 shares during the period. California Public Employees Retirement System lifted its holdings in shares of Penumbra by 7.9% during the second quarter. California Public Employees Retirement System now owns 61,027 shares of the company’s stock worth $15,661,000 after purchasing an additional 4,491 shares during the period. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Penumbra during the second quarter worth $1,137,000. 88.88% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Penumbra

In other news, Director Harpreet Grewal sold 100 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the transaction, the director owned 8,719 shares in the company, valued at $2,861,750.18. This trade represents a 1.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PEN shares. Citigroup decreased their price target on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. UBS Group reissued a “neutral” rating and issued a $374.00 target price on shares of Penumbra in a report on Thursday, February 26th. Wall Street Zen raised Penumbra to a “hold” rating in a report on Saturday, May 9th. Finally, Evercore reissued an “outperform” rating and issued a $335.00 target price on shares of Penumbra in a report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat, Penumbra presently has an average rating of “Hold” and a consensus price target of $361.33.

Get Our Latest Stock Analysis on PEN

Penumbra Trading Down 0.1%

Shares of PEN stock opened at $320.28 on Tuesday. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The stock has a market cap of $12.60 billion, a P/E ratio of 73.80, a P/E/G ratio of 1.96 and a beta of 0.71. The business has a fifty day simple moving average of $326.54 and a 200-day simple moving average of $326.64. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The firm had revenue of $374.76 million during the quarter, compared to analysts’ expectations of $370.47 million. During the same quarter in the prior year, the business earned $0.83 EPS. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. On average, analysts forecast that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.

About Penumbra

(Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.